Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) EV/Sales
As of 16 October 2026, Biogen Inc. (BIIB) trades at a EV/Sales of 4.0×. Over the past ten years it has ranged from 1.9× (April 2025) to 11.5× (March 2015); the current reading is higher than 53% of that period. That is in line with the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | 13.11% |
| FY2024 | 2.5× | (44.15%) |
| FY2023 | 4.5× | 12.20% |
| FY2022 | 4.0× | 15.73% |
| FY2021 | 3.5× | 5.90% |
| FY2020 | 3.3× | (14.81%) |
| FY2019 | 3.9× | (18.93%) |
| FY2018 | 4.8× | (20.26%) |
| FY2017 | 6.0× | 4.65% |
| FY2016 | 5.7× | (16.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.8× | 29.60% |
| Mar 2026 | 2.9× | 2.13% |
| Dec 2025 | 2.9× | 25.78% |
| Sep 2025 | 2.3× | 3.56% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 2.7× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| PFE Pfizer Inc. compare | 3.5× |
| NVO Novo Nordisk A/S compare | 3.6× |
| BIIB Biogen Inc. | 4.0× |
| AZN AstraZeneca PLC compare | 4.6× |
| GILD Gilead Sciences, Inc. compare | 7.1× |
| AMGN Amgen Inc. compare | 7.3× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement